Application of glucose transporter 1 inhibitor WZB117 to preparation of cystic echinococcosis treating drug

A technology for glucose transport and cystic echinococcosis, applied in drug combinations, anti-infective drugs, pharmaceutical formulations, etc., can solve problems such as poor absorption, unsatisfactory treatment effect, and long-term use

Pending Publication Date: 2020-11-06
THE FIRST TEACHING HOSPITAL OF XINJIANG MEDICAL UNIVERCITY
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The present invention provides an application of glucose transporter 1 inhibitor WZB117 as a drug for treating cystic echinococcosis, which can effectively solve the problem that there is no relevant report on glucose transporter 1 in

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of glucose transporter 1 inhibitor WZB117 to preparation of cystic echinococcosis treating drug
  • Application of glucose transporter 1 inhibitor WZB117 to preparation of cystic echinococcosis treating drug
  • Application of glucose transporter 1 inhibitor WZB117 to preparation of cystic echinococcosis treating drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1, the application of the glucose transporter 1 inhibitor WZB117 as a drug for the treatment of cystic echinococcosis.

Embodiment 2

[0031] Example 2, as an optimization of the above example, also includes the combined use of albendazole, glucose transporter 1 inhibitor WZB117 and albendazole.

Embodiment 3

[0032] Example 3, as an optimization of the above example, the mass ratio of glucose transporter 1 inhibitor WZB117 and albendazole is 1:8 to 1:1.

[0033] The application of the glucose transporter 1 inhibitor WZB117 as a drug for the preparation of cystic echinococcosis is tested as follows:

[0034] 1. In vitro experiment of glucose transporter 1 inhibitor WZB117

[0035] 1.1 WZB117 in vitro experiment

[0036] 1.1.1 Purpose of the experiment: To explore the survival rate of Echinococcus granulosus protoscoleum and vesicles in vitro with WZB117 at various concentrations for a period of 4 days

[0037] 1.1.2 Experimental grouping (overview)

[0038] This experiment was divided into 9 groups, namely WZB117 intervention group 1, WZB117 intervention group 2, WZB117 intervention group 3, WZB117 intervention group 4, WZB117 intervention group 5, WZB117 intervention group 6, ABZSO group, negative group and DMSO group; Three replicate wells were done in each group; the experimen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to the technical field of echinococcosis drugs, in particular to an application of a glucose transporter 1 inhibitor WZB117 to preparation of a cystic echinococcosis treating drug. The invention discloses the application of the WZB117 to preparation of the cystic echinococcosis treating drug for the first time. Pharmacodynamic experiment data in vivo and in vitro show that the WZB117 is an efficient echinococcosis-resistant drug molecule, and particularly has a remarkable treatment effect on cystic echinococcosis, and the effect is superior to that of albendazole sulfoxide which is an albendazole metabolite; the combined use of the WZB117 and the albendazole sulfoxide has a better synergistic treatment effect, and the effect is remarkably superior to that of independent administration of the WZB117 and independent administration of the albendazole sulfoxide; and meanwhile, the dosage of the combined use of the WZB117 and the albendazole sulfoxide is reduced by 1/3-1/2 compared with the dosage of the independent administration of the albendazole sulfoxide, so that the dosage and the drug resistance are greatly reduced, a good treatment effect is achieved, and the WZB117 can be used as an effective substitute for existing albendazole.

Description

technical field [0001] The invention relates to the technical field of echinococcosis drugs, and relates to the application of a glucose transporter 1 inhibitor WZB117 as a drug for treating cystic echinococcosis. Background technique [0002] Cystic echinococcosis (CE) is caused by Echinococcus granulosus ( Echinococcus granulosus ) larvae parasitic on livestock such as cattle and sheep or human body caused by zoonotic chronic parasitic diseases. The disease is distributed globally. It is mainly concentrated in the northwest agricultural and animal husbandry areas in China. The threatened population reaches 66 million, causing economic losses of more than 3 billion yuan each year. It is a serious public health problem that has attracted much attention. In 2006, the disease was included in the National Free Relief Program. [0003] The treatment methods for cystic echinococcosis mainly include surgical treatment and drug therapy, but surgical treatment has problems such ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/235A61K31/4184A61P33/10
CPCA61K31/235A61K31/4184A61P33/10A61K2300/00
Inventor 吕国栋林仁勇王慧库尔班尼沙·阿马洪刘辉毕晓娟杨宁李亮
Owner THE FIRST TEACHING HOSPITAL OF XINJIANG MEDICAL UNIVERCITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap